Skip to main content
  • Heart Attack and Stroke Symptoms
  • Volunteer
  • Learn CPR
  • ShopHeart
American Heart Association heart and torch logo
American Heart Association
  • Donate Once
  • Donate Monthly
  • donateDonate
  • Close Menu

    Trending Search

    • find my cpr card
    • bls
    • ecard
    • acls
    • bls certification
  • Healthy Living
  • Health Topics
  • Professionals
  • Get Involved
  • Ways to Give
  • About Us
  • Learn CPR
  • In Your Community
  • Heart Attack and Stroke Symptoms
  • Learn CPR
  • Volunteer
  • ShopHeart
  1. Home
  2. Around the AHA
  3. Newer Type 2 diabetes drugs could protect against both heart, kidney disease

Newer Type 2 diabetes drugs could protect against both heart, kidney disease

Taizhan Sakimbaev/EyeEm, Getty Images
(Taizhan Sakimbaev/EyeEm, Getty Images)

Two newer classes of drugs used to treat Type 2 diabetes have been shown to protect patients against heart disease and chronic kidney disease, in addition to their ability to help manage blood sugar.

Based on an analysis of clinical trials through March, a group of leading experts in diabetes, heart failure, kidney disease and cardiometabolic disease believe the medicines, known as sodium glucose co-transporter 2 (SGLT2) inhibitors and glucagon like peptide-1 receptor agonists (GLP-1 RAs), protect against heart and kidney disease and their serious complications. Doctors should consider the medicines when treating people with chronic kidney disease and Type 2 diabetes, the experts say.

The analysis is described in a new scientific statement from the American Heart Association, published Sept. 28 in the AHA's flagship journal, Circulation.

In the U.S., 26 million people have been diagnosed with diabetes, and over 9 million more have the condition but it hasn't yet been diagnosed. Type 2 diabetes is a leading cause of chronic kidney disease.

Experts reviewed evidence from large randomized controlled trials of the two classes of medicines in patients with Type 2 diabetes, chronic kidney disease and those who were at risk for, or already had, cardiovascular disease. The trial results showed that the drugs can safely and significantly reduce the risk of heart attack, stroke and death from cardiovascular disease, reduce hospitalization and slow the progression from chronic to end-stage kidney disease.

"A collaborative treatment approach among primary care doctors and specialists in diabetes, cardiology and kidney disease that, when indicated, includes treatment with these two classes of medications could add more heart (disease)- and kidney disease-free years and greatly extend survival for people with Type 2 diabetes," said the chair of the statement writing committee, Dr. Janani Rangaswami.

The most important question is how these medicines will be deployed in the clinic, said Rangaswami, associate chair of research in the department of medicine at Einstein Medical Center and associate clinical professor at the Sidney Kimmel College of Thomas Jefferson University, both in Philadelphia.

"When multidisciplinary teams can identify high-risk patients and ensure targeted delivery of these therapies, as appropriate, we could greatly reduce the burden of heart and kidney disease for millions of people with Type 2 diabetes," Rangaswami said.

About 37 million U.S. adults have kidney disease. Most patients with end-stage kidney disease have Type 2 diabetes, and people with Type 2 diabetes are at increased risk for high blood pressure, heart disease and stroke.

Besides people with Type 2 diabetes, the scientific statement identifies two other groups who might benefit from SGLT2 inhibitors and GLP-1 RA medications: people with heart failure with reduced ejection fraction with or without Type 2 diabetes, and people with chronic kidney disease who do not have Type 2 diabetes. The statement's authors anticipate more data emerging to validate the use of the two types of drugs for these at-risk patients.


Last Reviewed: Sep 28, 2020

X formerly known as Twitter Facebook LinkedIn Email Print

Around the AHA

Around the AHA
  • A Century of Heart
  • What Actually Happened
  • Honoree is a longtime AHA volunteer with a heart for service
  • What does the sugar in beverages do to your body?
  • Supporting heart health, one dish at a time
  • Singer Amy Grant reflects on rare heart condition that could have killed her
  • The Bugher Foundation has provided valuable funds, ideas to support AHA research, researchers

*All health/medical information on this website has been reviewed and approved by the American Heart Association, based on scientific research and American Heart Association guidelines. Find more information on our content editorial process.

American Heart Association

National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service
1-800-AHA-USA-1
1-800-242-8721

Contact Us

Hours
Monday - Friday: 7 a.m. – 7 p.m. CT 
Saturday: 9 a.m. - 5 p.m. CT
Closed on Sundays

Tax Identification Number
13-5613797

About Us

  • About the AHA/ASA
  • Our Impact
  • Annual Report
  • AHA Financial Information
  • International Programs
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom
  • Careers

Get Involved

  • Donate Now
  • Make a Memorial Gift
  • Ways to Give
  • Advocate
  • Volunteer
  • Go Red For Women
  • ShopHeart
  • ShopCPR

Our Sites

  • American Heart Association
  • American Stroke Association
  • CPR & ECC
  • Professional Heart Daily
  • More Sites
  • Facebook
  • Instagram
  • X formerly known as Twitter
  • Tik Tok
  • YouTube
  • LinkedIn
  • Pinterest
  • National Health Council Standards of Excellence Certification Program page for Standards of Excellence
  • Better Business Bureau page for American Heart Association
  • Charity Navigator Home
  • Secured by Sectigo page for SSL certificates
  • AHA Careers
  • Privacy Policy
  • Medical Advice Disclaimer
  • Accessibility Statement
  • Copyright Policy
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Whistleblower Policy
  • Content Editorial Guidelines
  • Suppliers & Providers
  • State Fundraising Notices


©2025 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.
The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress ™ DHHS, Go Red ™ AHA ; National Wear Red Day® is a registered trademark.

×
American Heart Association logo

This link is provided for convenience only and is not an endorsement of either the linked-to entity or any product or service.

Proceed